13797-77-8

Usage

Uses

Used in Pharmaceutical Research:
5-METHOXYPYRIDO[3,2-d]pyrimidine-2-amine, 97% is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Synthetic Chemistry:
In synthetic chemistry, 5-METHOXYPYRIDO[3,2-d]pyrimidine-2-amine, 97% serves as a key building block for the creation of more complex molecules. Its reactivity and structural features make it a valuable component in the synthesis of advanced materials and compounds.
Used in Drug Discovery:
5-METHOXYPYRIDO[3,2-d]pyrimidine-2-amine, 97% is employed as a potential candidate in drug discovery processes. Its properties may contribute to the development of new therapeutic agents, particularly in the areas of medicinal chemistry and biochemistry.
Used in Material Science:
In material science, 5-METHOXYPYRIDO[3,2-d]pyrimidine-2-amine, 97% may be used to develop novel materials with specific properties. Its incorporation into various systems could lead to advancements in areas such as electronics, coatings, and advanced materials.

Upstream product

• 13534-97-9 6-bromopyridine-3-amine 
• 67-56-1 methanol 
• 38533-61-8 2-chloro-6-methoxy-3-nitropyridine 
• 17356-08-0 thiourea 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 1147550-11-5 ammonium thiocyanate 
• 540-72-7 sodium thiocyanide 
• 505-14-6 thiocyanogen 
• 4548-45-2 2-chloro-5-nitropyridine 
• 333-20-0 potassium thioacyanate 
• 5446-92-4 2-methoxy-5-nitropyridine 

Downstream Products

• 131424-04-9 6-Methoxy-2-phenyl-[1,2,4]triazolo[5',1':2,3]thiazolo[5,4-b]pyridine 
• 131424-05-0 6-Methoxy-2-p-tolyl-[1,2,4]triazolo[5',1':2,3]thiazolo[5,4-b]pyridine 
• 131424-07-2 2-(4-Chloro-phenyl)-6-methoxy-[1,2,4]triazolo[5',1':2,3]thiazolo[5,4-b]pyridine 
• 131424-06-1 2-(2-Chloro-phenyl)-6-methoxy-[1,2,4]triazolo[5',1':2,3]thiazolo[5,4-b]pyridine 
• 866774-38-1 3-cyclopentyl-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-2-(4-nitrophenyl)propionamide 
• 933068-85-0 (R)-3-cyclopentyl-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-2-phenyl-propionamide 
• 1039016-45-9 C₂₂H₂₃N₅O₄S₂ 
• 866772-51-2 3-cyclopentyl-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-2-[4-(4-methyl-piperazine-1-sulfonyl)phenyl]propionamide 
• 1445883-67-9 C₁₄H₈N₄O₃S 
• 1445883-68-0 C₂₀H₁₉N₅O₄S 
• 1445883-69-1 C₂₀H₂₁N₅O₂S 
• 1445881-84-4 C₂₈H₃₁N₇O₄S 
• 42362-27-6 2,4-Diamino-6-(6-methoxy-2<1H>-thion-3-pyridyl)pyrimidinylamin 
• 81587-43-1 N-6'-methoxy-2'<1H>-thioxo-3'-pyridyl-2,4-dichloro-6-pyrimidinylamine 

Relevant academic research and scientific papers

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Polymerizable compound, polymerizable composition, polymer, and optically anisotropic material

The present invention relates to: a polymerizable compound (I), wherein Y1 to Y6 are a chemical single bond, —O—C(═O)—, —C(═O)—O— or the like, G1 and G2 are a divalent aliphatic group, Z1 and Z2 are an alkenyl group, Ax is a fused ring group represented by a formula (II), wherein X is —NR3—, an oxygen atom, a sulfur atom or the like, R3 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and D is a substituted or unsubstituted ring having 1 to 20 carbon atoms that includes at least one nitrogen atom, Ay is a hydrogen atom, an alkyl group, A1 is a trivalent aromatic group or the like, A2 and A3 are a divalent aromatic group having 6 to 30 carbon atoms or the like, and Q1 is a hydrogen atom, or an alkyl group having 1 to 6 carbon atoms.

Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.

PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.

7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of Ρ2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.

HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF

The present invention relates to a heterocyclic pyridone compound represented by General Formula (I), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-Met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method. The present invention further relates to a pharmaceutical composition containing the heterocyclic pyridone compound as an active ingredient, and a use of the pharmaceutical composition in treatment of diseases associated with tyrosine kinase c-Met, especially cancer associated with c-Met, as a medicament.

TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF

The present invention relates to a tri-heterocyclic derivatives, preparation process and uses thereof, specifically relates to a tri-heterocyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, preparation process, and further relates to a pharmaceutically acceptable composition comprising compounds of formula (I), or a pharmaceutically acceptable salt thereof, and their pharmaceutical use as inhibitors of kinase.

TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF

The present invention relates to a tri-heterocyclic derivatives, preparation process and uses thereof, specifically relates to a tri-heterocyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, preparation process, and further relates to a pharmaceutically acceptable composition comprising compounds of formula (I), or a pharmaceutically acceptable salt thereof, and their pharmaceutical use as inhibitors of kinase

NOVEL COMPOUNDS

The invention is directed to certain novel compounds. Specifically, the invention directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular Itk activity.

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes

Type 2 diabetes is a polygenic disease which afflicts nearly 200 million people worldwide and is expected to increase to near epidemic levels over the next 10-15 years. Glucokinase (GK) activators are currently under investigation by a number of pharmaceu